bachelorThesis
Resistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-Colombia
Fecha
2012-11-14Registro en:
Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases
mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-
26.
Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among
patients with advanced human immunodeficiency virus infection. HIV Outpatient Study
Investigators. N Engl J Med 1998;338:853-60.
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
January 10, 2011. The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents –
A Working Group of the Office of AIDS Research Advisory Council (OARAC).
Masquelier B, Lemoigne E, Pellegrin I, Douard D, Sandler B, Fleury HJ. Primary infection
with zidovudine-resistant HIV. N Engl J Med 329(15):1123–1124 (1993).
David A.M.C. van de Vijver, Annemarie M.J. Wensing, Charles A.B. Boucher, Department of
Medical Microbiology, University Medical Centre Utrecht, Utrecht, the Netherland. The
Epidemiology of Transmission of Drug Resistant HIV-1, 2008.
Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently
infected with HIV. N Engl J Med. 2002;347(6):385-394.
Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance
associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS.
2010;24(8):1203-1212.
Wensing AM, Van De Vijver D, Asjo B. Analysis from more than 1600 newly diagnosed
patients with HIV from 17 european countries shows that 10% of the patients carry primary
drug-resistance: The Catch Study. 2nd International AIDS Society Conference on HIV
pathogenesis and treatment; Paris July 13-16, 2003; Abstract lb1.
Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al. Evolving
patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002;
16: 1511-9.
Toni T, Masquelier B, Bonard D et al. Primary HIV-1 drug resista
Petroni A, Deluchi G, Pryluka D et al. Update on primary HIV-1 resistance in Argentina:
emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase
inhibitors in drug-naive patients. J Acquir Immune Defic Syndr 42(4):506–510 (2006).
Truong HH, Grant RM, McFarland W et al. Routine surveillance for the detection of acute
and recent HIV infections and transmission of antiretroviral resistance. AIDS 20(17):2193–2197
(2006).
Rodrigues R, Scherer LC, Oliveira CM et al. Low prevalence of primary antiretroviral
resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed
individuals from south Brazil. Virus Res 116(1–2):201-207 (2006).
Brindeiro RM, Diaz RS, Sabino EC et al. Brazilian Network for HIV Drug Resistance
Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 17(7):1063–
1069 (2003).
Lama JR, Sanchez J, Suarez L et al. Linking HIV and antiretroviral drug resistance
surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune
Defic Syndr 42(4):501–505 (2006).
Frentz, Dineke, Boucher, Charles A. B. and van de Vijver, David A. M. C. (2012),
"Temporal Changes in the Epidemiology of Transmission of Drug-Resistant HIV-1 across the
World", AIDS Reviews
Truong HH, Grant RM, McFarland W et al. Routine surveillance for the detection of acute
and recent HIV infections and transmission of antiretroviral resistance. AIDS 20(17):2193–2197
(2006).
Lama JR, Sanchez J, Suarez L et al. Linking HIV and antiretroviral drug resistance
surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune
Defic Syndr 42(4):501–505 (2006).
DiazGranados, C. Mantilla, W.Lenis, W. n Antiretroviral drug resistance in HIV-infected
patients in Colombia. International Journal of Infectious Diseases 2010;14:e298–e303.
Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside
reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in
treatment-naive HIV-1-infected subjects. J Infect Dis. 2008;197(6):867-870.
Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination
HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007 May;4(2):65-72
Oette M, Kaiser R, Daumer M et al. Primary HIV drug resistance and efficacy of first-line
antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41(5):573–581
(2006).
Weinstock HS, Zaidi I, Heneine W et al. The epidemiology of antiretroviral drug resistance
among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189(12):2174–2180
(2004).
Novak RM, Chen L, MacArthur RD et al. Prevalence of antiretroviral drug resistance
mutations in chronically HIV-infected, treatment-naive patients: implications for routine
resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 40(3):468–474
(2005)
Jayaraman GC, Archibald CP, Kim J et al. A population-based approach to determine the
prevalence of transmitted drug-resistant HIV among recent versus established HIV infections:
results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune
Defic Syndr 42(1):86–90 (2006).
Poon AF, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, Rodríguez B, Boswell
SL, Frost SD, Haubrich RH. PLoS One. 2011;6(6):e21189. Epub 2011 Jun 20. Transmitted
drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and
effects on pre-therapy CD4 and viral load
Palella FJ, Jr., Armon C, Buchacz K, et al. The association of HIV susceptibility testing with
survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern
Med 2009;151:73-84
Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to
antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of
resistance testing trial. Clin Infect Dis 2004;38:723-30.
Barbour, JD, Hecht, FM, Wrin, T, et al. Persistence of primary drug resistance among
recently HIV-1 infected adults. AIDS 2004; 18:1683.
Weinstock, HS, Zaidi, et al. The epidemiology of antiretroviral drug resistance among drugnaive
HIV-1 infected person in 10 US cities. J Infect Dis 2004; 189:2174
Tommy F. Liu and Robert W. Shafer. Web Resources for HIV Type 1 Genotypic-Resistance
Test Interpretation. CID 2006:42 (1 June).
Antonella Cingolania, Antinorib, Rizzoa, Murria, Ammassaria, Baldinia, Di Giambenedettoa,
Caudaa and De Lucaa. Usefulness of monitoring HIV drug resistance and Adherence in
individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS
2002, 16:369±379.
Grant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance
among recently infected persons. JAMA 288(2):181–188 (2002).
Harzic M, Pellegrin I, Deveau C et al. Genotypic drug resistance during HIV-1 primary
infection in France (1996–1999): frequency and response to treatment. AIDS 16(5):793-796
(2002).
Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006
recommendations of the International AIDS Society-USA panel. JAMA 296(7):827–843 (2006).
Vandamme AM, Sonnerborg A, it-Khaled M et al. Updated European recommendations for
theclinical use of HIV drug resistance testing. Antivir Ther 9(6):829–848 (2004).
Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatmentnaive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41(9):1316-
1323.
Martin S. Hirsch, Gunthard, Schapiro, Brun-Vezinet, Clotet, Hammer, Johnson, Kuritzkes,
Mellors, Pillay,Yeni, Jacobsen, and Richman. Antiretroviral Drug Resistance Testing in Adult
HIV-1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel. CID
2008:47 (15 July)
Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van
Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer. Predictive Value
of HIV-1 Genotypic Resistance Test Interpretation Algorithms. Journal of Infectious Diseases,
2009 Aug 1;200(3):453-463
Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, et al. (2010) Transmitted Drug
Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009. PLoS ONE 5(12):
e15510. doi:10.1371/journal.pone.0015510.
Bennet DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug
Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update.
PLoS ONE 2009: 4(3);1-8. e4724
Victoria A. Johnson, MD, Françoise Brun-Vézinet, MD, PhD, Bonaventura Clotet, MD,
PhD, Huldrych F. Günthard, MD, Daniel R. Kuritzkes, MD, Deenan Pillay, MD, PhD, Jonathan
M. Schapiro, MD, and Douglas D. Richman, MD. Update of the Drug Resistance Mutations in
HIV-1: December 2010. International AIDS Society–USA, Volume 18 Issue 5 December 2010.
Cohen et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy N Engl J Med.
2011; 365: 493-505.
Ocfemia C B, Kim D, Ziebell R, et al. Prevalence and trends of transmitted drug
resistance-associated mutations by duration of infection among persons newly
diagnosed with HIV-1 infection: 5 states and 3 municipalities, US, 2006 to 2009. Infections;
March 5-8, 2012; Seattle, Washington. Clinical Care Options.
Guía de práctica clínica de VIH/SIDA. Recomendaciones basadas en la evidencia, Colombia.
Asociación Colombiana de Infectología, vol. 10 - 4, 2006.
157927
TE05622
Autor
Galindo Quintero, Jaime
Martínez Cajas, Jorge
Institución
Resumen
Se realizo un estudio para determinar la frecuencias de resistencias trasmitidas del HIV in pacientes atendidos en la Corporación de Lucha contra el SIDA en Cali, Colombia. Se incluyeron pacientes con infección por VIH confirmada nunca expuestos a tratamiento antirretroviral y que tuvieran estudio genotípico de resistencia en el periodo del 2008 al 2010. Adicionalmente fueron incluidos en el análisis factores socio-demográficos y condiciones relacionadas con el VIH. 152 pacientes fueron incluidos, la frecuencia de resistencia primaria fue del 13.2%. Para NNRTI se encontró mutaciones de resistencia en 5.3%, para NRTI en 4.6% y para IP en 2.0%. La frecuencia de resistencia primaria en este estudio es más alta a la encontrada en estudios previos en Colombia y similar a la de otros países con mayor uso de antirretrovirales.